Seeking Alpha

TScan Therapeutics Presents Promising Updated Phase 1 Clinical Results on TSC-100 and TSC-101 at the 2024 Tandem Meetings of ASTCT and CIBMTR

All eight (100%) treatment-arm patients are relapse-free and have achieved and maintained complete donor chimerism following treatment with TSC-100 or TSC-101 Patient with high-risk, TP53-mutated MDS ...
Seeking Alpha

TScan Therapeutics Announces Best Abstracts Award and Upcoming Oral Presentation at the 2024 Tandem Meetings of ASTCT and CIBMTR

Location: Stars at Night B2 & B3 (Ballroom Level, Henry B. González Convention Center) A copy of the presentation materials will be added to the “Events and Presentations” section of the Company’s ...
Business Wire

TScan Announces Collaboration with Novartis on the Discovery and Development of Novel T Cell Receptor Therapies for the Treatment of Solid Tumors

WALTHAM, Mass.--(BUSINESS WIRE)--TScan Therapeutics, a biopharmaceutical company focused on the development of T cell receptor (TCR) therapies which reprogram a patient’s own T cells to recognize ...
Business Insider

TScan Therapeutics Appoints Commercial Leader Stephen Camiolo as Senior Vice President, Market Access

WALTHAM, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell ...
Benzinga.com

Why Is TScan Therapeutics Stock Gaining Today?

TScan Therapeutics, Inc. (NASDAQ:TCRX) shares are trading higher in the premarket session on Thursday. The firm announced a significant financing deal, entering into a securities purchase agreement ...
Business Insider

TScan Therapeutics Refinances Existing Convertible Debt Facility with Term Loan for up to $52.5 Million from Silicon Valley Bank

WALTHAM, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell ...
Nasdaq

Breaking Down TScan Therapeutics: 4 Analysts Share Their Views

Ratings for TScan Therapeutics (NASDAQ:TCRX) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. Summarizing their recent assessments, the table ...
Nasdaq

TScan Therapeutics Announces 2023 Clinical Plans and Highlights Recent Progress

Phase 1 umbrella trial of TSC-100 and TSC-101 active in five sites; on track to enroll first two cohorts in 1H 2023 with interim data by end of 2023 Advancing solid tumor program with development of ...
FierceBiotech

TScan adds another $100M to the pot as it plots new TCR cancer trials

TScan Therapeutics has raised a cool $100 million in a series C to start 2021 on the positive notes it rang throughout 2020. Boston area-based TScan launched in July 2019 with the goal of identifying ...
Business Wire

TScan Therapeutics Formed to Overcome Challenges of Current Immunotherapies with Novel TCR Discovery Platform and $48 Million in Funding

BOSTON--(BUSINESS WIRE)--TScan Therapeutics, dedicated to unleashing the power of the immune system through life-changing T cell therapies, today announced its Series B financing, with over $48 ...
Benzinga.com

Why Are TScan Therapeutics Shares Are Shooting Higher Today

Amgen Inc AMGN and TScan Therapeutics Inc TCRX announced a multi-year collaboration to use TScan's proprietary target discovery platform, TargetScan, to identify the antigens recognized by T cells in ...